R N Gupta, J Bioequiv Availab 2014, 6:5
http://dx.doi.org/10.4172/0975-0851.S1.019

OMICS Group Conferences
Accelerating Scientific Discovery

5th World Congress on
Bioavailability and Bioequivalence
Pharmaceutical R&D Summit

September 29-October 01, 2014 DoubleTree by Hilton Baltimore-BWI Airport, USA

Bioavailability and bioequivalence study: Need of hour for patient safety

R N Gupta
Birla Institute of Technology, India

The development of Pharmaceutical formulations shifted from traditional formulations towards "Novel Drug Delivery System". At the same time new drug molecules having better therapeutic response are also being introduced. Besides this, there are several new polymers introduced by "Polymer Scientist" useful in development of "Novel Drug Delivery System" of new molecule for better and desired therapeutic action in patients. Evaluation of formulation is being done after its development. Dissolution study is one of them, for doing *in vitro* study of formulation for knowing its release from the used polymer of developed formulation at desired rate. But for knowing its availability in biological system the *in vivo* study is being conducted known as "Bioavailability study". Further since several scientists are developing formulations of similar molecules at different places, hence the Bioequivalence study is become a necessity of those formulations. In view of above for providing better therapeutic response in patients with minimum & modified dose, the "Bioavailability and Bioequivalence study" is the need of hour for patient safety.

rngupta@bitmesra.ac.in